Pharmaceutical purchase and sale anti-corruption re-start late patent cliff finally came.

Author . . . Felix Yao recently, the National Health And Wellness Commission Medical and Medical Administration news, to correct the pharmaceutical purchase and sale of the field and medical services in the wrong wind, 2020 wind control work to continue to crack down on fraud to cheat health insurance funds, consolidate the pharmaceutical circulation of the field of anti-wind effectiveness, resolutely clean up the industry chaos.
the purchase and sale of medicine price control has been a major problem in the pharmaceutical industry, not only at home, but also abroad, but also directly or indirectly lead to the "patent cliff" of drugs delayed.
June, the U.S. District Court for the District of Connecticut issued a lawsuit in which a number of multinational drug companies became court", including noted multinational pharmaceutical giants such as Novarma, Pfizer and Mylan.
26 generic drug companies to participate in the revision of at least 80 generic drug prices, mainly for the treatment of skin diseases.
agreements between generic drug makers to ensure their "fair share" of the market and to prevent "price crushes" caused by excessive competition.
standard model for manipulating drug prices in the U.S.: pharmaceutical companies modify and determine generic drug prices, reduce competition, and unreasonably restrict the trade in generic drugs across the U.S. through academic conferences and other forms.
Washington Post pointed out that the entire U.S. pharmaceutical industry is riddled with price monopoly programs, the U.S. pharmaceutical industry has become a persistent problem.
multinational drug companies are still on Big Brother's doorstep, as well as in China.
chinese patent cliff is decades late than the United States China's pharmaceutical industry is relatively lagging behind, national pharmaceutical companies have been suppressed by multinational pharmaceutical companies, especially in the pricing of innovative drugs.
multinational pharmaceutical companies through drug innovation advantages, strengthen corporate brands, thereby affecting pharmaceutical policy makers, access to price protection.
After the expiration of the patent for innovative drugs, continue to hype the concept of "original research drugs", continue to enjoy policy dividends, access to a large number of profits back-feeding country of origin research and development, and national pharmaceutical enterprises are limited by the policy, as a younger brother has been passively beaten, become the family's "gas package."
Pfizer China will have 2.57 billion USDs in revenue in 2019, accounting for 26% of the world's total, making it one of the "beneficial policies" of multinational drug companies, while AstraZeneta's sales in China have quadrupled sevenfold in a decade, according to data.
This is only the tip of the iceberg, in fact, China's multinational pharmaceutical companies hundreds, accounting for most of China's pharmaceutical market share, thanks to long-term policy asylum, leading to the national pharmaceutical companies vietnam war weaker, in the micro-profit generic drug market rarely a piece of the scraps.
this situation continues into 2018, after the establishment of the "super health insurance bureau", marking the entry of health insurance into the deep water, policy knife, knife hit the key.
from the consistent evaluation, with volume procurement, medical insurance negotiations access, are constantly refreshing the people's awareness of multinational pharmaceutical companies, patented drugs are gradually from the "gods" down.
why is the patent cliff so late? The original research drug is flat, the original research drug has the quality advantage, from the raw material drug selection, production process has a leading edge.
Pfizer Dalian plant live happy production workshop from the pressure sheet, plastic seal, packaging and sealing, to achieve the whole process of unmanned operation.
and brand advantage has always been the basis for the survival of multinational pharmaceutical companies, from corporate brands to product brands will be national pharmaceutical enterprises out of dozens of streets.
long-term public welfare construction, to promote multinational pharmaceutical companies in China's brand value-added.
2015, Novaral Group (China) was awarded the 2015 Outstanding Corporate Citizen of China, and the Novarda Southwest Forestry Carbon Sink, Community and Biodiversity Project was awarded the 2015 Outstanding Public Welfare Project for Chinese Enterprise Citizens in a scientific assessment by the Corporate Citizenship Committee of the China Federation of Social Work.
strengthen the corporate brand through public welfare donations in emergencies.
In addition to donations from the United States and Europe, in China, Wesser has donated Rmb1m (about 15m yen) to the non-profit Wuhan Charity Federation and provided medicines and medical aid to local medical institutions through its Chinese subsidiary.
is only a microcosm of multinational pharmaceutical companies to establish corporate brands, long-term brand building to help them win the national pharmaceutical enterprises.
brand building is a century-old multinational pharmaceutical companies to play.
Relying on brand building in-depth people, rumors spread that "Pfizer collection of streaming standard products to sell", the original author believes that Pfizer Lipto and Live Joy from the brand strength in hospitals and patients, which is separate from Pfizer's decades of high brand building investment.
high drug premiums until 2017 have contributed to the continued growth of high-priced original drug sales, which has been the driving force for multinational pharmaceutical companies to win the channel for high-priced drugs.
hospital drug increase is an important source of hospital revenue.
the higher the price of drugs, the greater the sales volume, for hospitals to obtain rich profits, multinational pharmaceutical companies over-patented drugs still rely on high prices in the channel to obtain a competitive advantage.
with gold sales also provides a more flexible operating space for high-priced original research drugs before 2013, multinational pharmaceutical companies with academic promotion umbrella, through a large number of academic conferences to explain the quality of their drugs and the clinical advantages of the brand.
the GSK incident, foreign companies have been identified under the guise of academic promotion, and a large number of fakes have become a means for pharmaceutical representatives to collect sales costs, while compliance has become a department to protect businesses, not a real compliance department.
at an annual meeting, the head of corporate compliance publicly declared that compliance was only for the protection of businesses and representatives in compliance with U.S. overseas anti-corruption laws, not to require purely academic promotion by sales representatives.
, multinational pharmaceutical companies can no longer deceive the public and patients, especially the ultra-high prices, for their gold sales to provide operating space.
August, the Central Commission for Discipline Inspection website once again put forward "severe punishment of drug corruption", this time for foreign enterprises with huge sales space is another test, how to deal with will not only be the enterprise compliance department, but the whole enterprise is facing a new issue.
, medicine from the rise of the media, many such as recording, breaking news, screen-screen events are emerging, pharmaceutical sales are completely "naked" in the media spotlight.
Multinational pharmaceutical company brand advantages, with gold sales and hospital fees hinder the realization of China's patent cliff, with the abolition of hospital fees, multinational pharmaceutical companies to strengthen compliance, sales costs reduced, can protect its high-priced drugs the only "brand."
and consistent evaluation to promote, the quality of national pharmaceutical enterprises standardized, and the original research drug equivalent, the era of equivalent will also come, patent expired drug price reduction has become inevitable.
The patent cliff or will achieve the post-2018 series of market-oriented reform accelerated ushered in a late "patent cliff", consistent evaluation, the establishment of the Health Insurance Bureau and volume procurement and a series of recurring policies, become the catalytic factors that induce the patent cliff.
consistent evaluation breaks the implementation of expired patent drug blindness from the 2016 generic drug consistency evaluation, the quality of domestic generic drugs and original research drugs on the same order, and gradually break the patient's dependence on high-priced original drugs.
quality improvement of generic drugs, high-priced original research drugs, patent cliff common sense and scientific evidence around the world once again show that the difference between over-patented drugs and through consistent evaluation of domestic drugs without clinical efficacy.
Multinational pharmaceutical companies are still engaged in a deadly struggle, CDE consistency evaluation policy is in full swing, some multinational pharmaceutical companies in opposition to consistency evaluation, in the open academic conference publicly put forward that biological ethonability and clinical ethonorability are different, through the consistent evaluation of BE trials, only to prove biological ethonthonology, but the differences between the two clinically exist, and attempt to hype the concept.
the question of whether clinical studies have confirmed the difference between the efficacy and safety of patented and generic drugs? The National Health Insurance Administration, established in 2018, has a greater say in paying for health-care funding and reduces overspending on alternative, high-priced drugs.
"Super Health Insurance Authority" has spared no effort to reduce expired patented drugs, even though the price of patented drugs has been significantly reduced through negotiated access, with the goal of being the lowest in the world, and AstraZenecom's net reduction to the lowest global price in 2019 is a good example.
negotiated access not only reduces overspending on expired patented drugs, but also provides a good model for reducing patented drugs to the lowest levels in the world.
The "patent cliff" with Chinese characteristics: with the volume of procurement exclusive winning bid and agreed to the national 10%-15% of the procurement volume mechanism, appropriate guidance of high-quality generic drugs and the original research drug market competition, crowding out the false high price of the drug moisture, which is also the original research drug in the volume of procurement after the implementation of the real sense of the "patent cliff" direct reason.
national volume procurement is the Chinese patent cliff tangible "hands", to help a large number of expired patented drugs for price dive, since not protected by patents, prices should not be protected.
In the national collection is inevitable, but not into the national collection, through a certain time limit, also need to be consistent with the price of the collection products, leaving multinational pharmaceutical companies with little time left, three years or less, and conceptual speculation will be futile.
decades, China's pharmaceutical industry is still lagging behind, but with the deepening of medical reform gradually began to integrate with the world, especially in policy rule-making, not only learn from the successful experience of developed countries in Europe and the United States, but also have global innovation.
Although China's patent cliff came late, but will not be blinded by the "pseudo-concept", and ultimately from the concept and action to help expired patented drugs to achieve "price dive", which also for the national pharmaceutical companies to buy time to promote their market competition.
It is true that multinational pharmaceutical companies have played an important role in the history of China's pharmaceutical development, advanced management concepts, training a large number of global thinking of pharmaceutical talent, innovative therapeutic drugs, the establishment of pharmaceutical brand promotion model, these will continue to be maintained in China.
.